CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Par Pharmaceutical, Inc. v. Mankind Pharma Limited <b><font color="red">PURSUANT TO COURT ORDER, DOCKET IN LEAD CASE 2:23CV400</font></b>

2:23-cv-00399

Overview

Case Number 2:23-cv-00399
Filing Date 2023-09-01
Status Terminated
Termination Date 2024-12-10
Court District Court, E.D. Texas (txed)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mankind Pharma Limited NPE (University / Research)

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Endo Par Innovation Company, LLC Operating Company

Represented By

1 Attorneys Listed

Andrea Leigh Fair

Ward, Smith & Hill, PLLC

Tel: +1 (903) 757-6400
Fax: +1 (903) 757-2323

1507 Bill Owens Parkway, Longview, TX 75604

Par Pharmaceutical, Inc. Operating Company

Represented By

1 Attorneys Listed

Andrea Leigh Fair

Ward, Smith & Hill, PLLC

Tel: +1 (903) 757-6400
Fax: +1 (903) 757-2323

1507 Bill Owens Parkway, Longview, TX 75604

Court & Judges

Court

District Court, E.D. Texas (txed)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 3 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 1 proceeding
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (3): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (1 found):
U.S. Courts: 1
U.S. District Court 2023-09-01
2:23-cv-00400

Par Pharmaceutical, Inc. v. Alkem Laboratories Ltd.

Asserted Patent
Status: TXED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US11717524
Varenicline compound and process of manufacture thereof
Filed: 2022-09-09
Issued: 2023-08-08
Active (15.4 yrs remaining)
Expires: 2042-04-15

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term; injunctive relief viable.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. Standard Maintenance Fee Schedule Tracked.

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

4

Dispositive

1

Granted

0

Denied

0

Pending / Review

4

Motions by Category

Procedural / Extension Motion 3 Motion for Preliminary Injunction / TRO 1

Key Dispositive Motions & Rulings

Motion for Preliminary Injunction / TRO Pending / Under Review
SEALED MOTION PLAINTIFFS MOTION FOR EXPEDITED DISCOVERY AND TEMPORARY RESTRAINING ORDER by Endo Par Innovation Company, LLC, Par Pharmaceutical, Inc.. (Attachme...
Entry #5 • 2023-09-01 Document →
Procedural / Extension Motion Pending / Under Review
Order on Motion for Extension of Time to File Response/Reply
Entry #41 • 2023-10-19 Document →
Procedural / Extension Motion Pending / Under Review
Order on Motion for Extension of Time to File Response/Reply
Entry #35 • 2023-10-10 Document →
Procedural / Extension Motion Pending / Under Review
MOTION to Seal (For Leave to File Under Seal) by Endo Par Innovation Company, LLC, Par Pharmaceutical, Inc.. (Attachments: # 1 Proposed Order)(Fair, Andrea) (En...
Entry #4 • 2023-09-01 Document →

Docket Entries

(66 total)
Pleading / Complaint

COMPLAINT against Mankind Pharma Limited ( Filing fee $ 402 receipt number ATXEDC-9685246.), filed by Par Pharmaceutical, Inc., Endo Par Innovation Company, LLC. (Attachments: # 1 Civil Cover Sheet, # 2 Exhibit 1 - US Patent No. 11,717,524, # 3 Exhibit 2 - Control of Nitrosamine Impurities in Human Drugs, Guidance for Industry, U.S. Food and Drug Administration Center for Drug Evaluation and Research (Feb. 2021, Rev. 1), # 4 Exhibit 3 - Laboratory analysis of varenicline products, FDA Feb. 8, 2022, # 5 Exhibit 4 - First Notice Letter, # 6 Exhibit 5 - Drugs@FDA Website, # 7 Exhibit 6 - Second Notice Letter, # 8 Errata 7 - Letter from J. Lessler to M. Black, dated August 14, 2023, # 9 Exhibit 8 - Letter from M. Black to J. Lessler, dated August 15, 2023, # 10 Exhibit 9 - E-mail from J. Lessler to M. Black, dated August 17, 2023, # 11 Exhibit 10 - E-mail from R. Rhoad to J. Lessler, dated August 23, 2023, # 12 Exhibit 11 - E-mail from J. Lessler to R. Rhoad, dated August 24, 2023 (with attachment), # 13 Exhibit 12 - E-mail from R. Rhoad to J. Lessler, dated August 25, 2023 (with attachments), # 14 Exhibit 13 - E-mail from R. Rhoad to J. Lessler, dated August 29, 2023)(Fair, Andrea) (Entered: 09/01/2023)

Entry #1 • 2023-09-01
1

Notice of Filing of Patent/Trademark Form (AO 120). AO 120 mailed to the Director of the U.S. Patent and Trademark Office. (Fair, Andrea) (Entered: 09/01/2023)

Entry #2 • 2023-09-01
1

Fed. R. Civ. P. 7.1(a)(1) Disclosure Statement filed by Endo Par Innovation Company, LLC, Par Pharmaceutical, Inc. identifying Other Affiliate Endo International PLC for Endo Par Innovation Company, LLC, Par Pharmaceutical, Inc.. (Fair, Andrea) (Entered: 09/01/2023)

Entry #3 • 2023-09-01
1
Procedural / Extension Motion Pending / Under Review

MOTION to Seal (For Leave to File Under Seal) by Endo Par Innovation Company, LLC, Par Pharmaceutical, Inc.. (Attachments: # 1 Proposed Order)(Fair, Andrea) (Entered: 09/01/2023)

Entry #4 • 2023-09-01
1
Motion for Preliminary Injunction / TRO Pending / Under Review

SEALED MOTION PLAINTIFFS MOTION FOR EXPEDITED DISCOVERY AND TEMPORARY RESTRAINING ORDER by Endo Par Innovation Company, LLC, Par Pharmaceutical, Inc.. (Attachments: # 1 Proposed Order, # 2 Affidavit/Declaration - Bradley, # 3 Affidavit/Declaration - Jarosz, # 4 Affidavit/Declaration - Dodds, # 5 Affidavit/Declaration - Rhoad, # 6 Exhibit 1, # 7 Exhibit 2, # 8 Exhibit 3, # 9 Exhibit 4, # 10 Exhibit 5, # 11 Exhibit 6, # 12 Exhibit 7, # 13 Exhibit 8, # 14 Exhibit 9, # 15 Exhibit 10, # 16 Exhibit 11, # 17 Exhibit 12, # 18 Exhibit 13, # 19 Exhibit 19, # 20 Exhibit 20)(Fair, Andrea) (Entered: 09/01/2023)

Entry #5 • 2023-09-01
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc